Beijing Weici Technology raises Series B for ultra-weak magnetic field medical imaging
What's the deal? Weici Technology, a Chinese medtech startup specialising in ultra-weak magnetic field measurement, has closed a Series B round worth several hundred million yuan. The round was backed by JingGuoSheng, JingGuoGuan, Beijing Pharmaceutical Health Fund, Beijing Quantum Fund, Cornerstone Venture Capital, and CASSTAR.
The company has developed a proprietary technology platform for measuring extremely weak magnetic fields. It applies this tech to two high-value clinical areas: precision detection of cardiovascular diseases and brain science research.
Weici's flagship products include a magnetocardiography (MCG) imaging device and a magnetoencephalography (MEG) system — both built entirely on its own intellectual property.
Why now? China is pushing hard to localise advanced medical imaging equipment and reduce dependence on foreign suppliers. Quantum sensing and ultra-weak magnetic measurement are gaining traction as next-generation diagnostic tools, particularly for non-invasive cardiac and neurological screening.
The investor mix — heavy on Beijing-based government-backed funds including a dedicated quantum fund — signals strong policy alignment. Municipal and state capital is flowing into quantum-adjacent technologies that can demonstrate near-term clinical and commercial applications.
What could go wrong? Magnetocardiography and magnetoencephalography remain niche clinical tools globally. Winning regulatory approvals, securing hospital adoption, and proving cost-effectiveness against established imaging modalities like MRI are all significant hurdles.
Government-heavy funding can also be a double-edged sword: it validates the technology politically, but commercial viability still needs to be proven in competitive healthcare markets.
The signal: Dealroom classifies Weici Technology as a "breakout" stage company, suggesting meaningful commercial traction beyond a typical Series B medtech startup. The investor syndicate — dominated by Beijing municipal investment funds spanning healthcare, quantum technology, and industrial holdings — underscores how Chinese public capital is converging around quantum-sensing applications with clear clinical pathways, positioning non-invasive magnetic imaging as a strategic priority rather than a speculative bet.
